Neurotech Pharmaceuticals announced the first commercial manufacturing, shipment, and surgical procedure of ENCELTO, the ...

Revakinagene taroretcel（NT-501）是一种封装细胞疗法，能够产生睫状神经营养因子（ciliary neurotrophic factor, CNTF）。在 2 期试验中，该疗法已显示出减缓黄斑毛细血管扩张症 2 型（macular telangiectasia type 2, MacTel）患者视网膜退化的效果。MacTel ...

In a new development for patients suffering from macular telangiectasia type 2 (MacTel), a rare and progressive retinal ...

For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, ...

Vision loss caused by a blinding eye disease can be slowed with a neuroprotective surgical implant, according to a study.

The eye implant, called ENCELTO, gradually releases proteins that protect light-sensing nerve cells against macular telangiectasia (MacTel) type 2, researchers recently reported in the journal NEJM ...

MacTel type 2 is a rare retinal condition causing central vision loss, with no current treatments available. NT-501, a potential treatment for MacTel, has its FDA decision delayed to March 18 ...